NCT01863914View on ClinicalTrials.gov

Vascular Protective Effect of Rosuvastatin in Arteriovenous Fistula

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

December 31, 2018

Study Completion Date

January 31, 2019

Conditions
End-stage Kidney DiseaseDiabetes MellitusArteriovenous Fistula
Interventions
DRUG

Rosuvastatin

Arteriovenous fistula surgery was performed after 1-week treatment with placebo or Rosuvastatin (randomized, double blind). The intervention drug treatment continues for 3 more weeks after creation of AV fistula.

Trial Locations (1)

704

National Cheng Kung University Hospital, Tainan City

All Listed Sponsors
lead

National Cheng-Kung University Hospital

OTHER

NCT01863914 - Vascular Protective Effect of Rosuvastatin in Arteriovenous Fistula | Biotech Hunter | Biotech Hunter